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Angioimmunoblastic T-cell lymphoma (AITL) is a malignancy
of mature T-cells. It is characterized as a polymorphic lym-
phonodal lymphoid inﬁltrate accompanied by prominent
proliferation of endothelial venules and follicular den-
dritic cells. AITL was ﬁrst described in 1974 by Frizzera
et al. as an angioimmunoblastic lymphadenopathy with
dysproteinemia.1 A short time later, the name was changed to
immunoblastic lymphadenopathy, and then to lymphogranu-
lomatosis X in 1979.2
AITL comprises 15–20% of all peripheral T-cell lymphomas
and 1–2% of all non-Hodgkin lymphomas (NHL). Most fre-
quently, it occurs in aged patients, with equal prevalence
between males and females. Typically, AITL displays an
aggressive behavior, which makes the diagnosis difﬁcult and it
must be differentiated from other malignant lymphoprolifera-
tive diseases, drug reactions and viral infections. Patients with
AITL frequently exhibit B-symptoms (e.g., fever and weight
loss) and a generalized enlargement of the lymph nodes. Other
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reserved.common symptoms include hepatomegaly, splenomegaly,
polymorphic skin rash and pleural effusion. Advanced stage
disease (Ann Arbor III/IV) is observed in 80% of cases. AITL
is also associated with autoimmune phenomena. Polyclonal
hypergammaglobulinemia occurs in approximately 50% of
AITL cases.3
Histological analyses of AITL specimens show effacement
of the lymph node architecture, particularly in advanced
stages. Malignant cells tend to distribute into interfollicular
regions, and are typically positive for T-helper cell markers and
T-cell receptors (TCRs) alpha and beta.2,4 Immunoblasts, often
positive for Epstein–Barr virus (EBV), are frequently dispersed
in paracortical regions. This characteristic can be confused
with Reed-Sternberg cells, which can lead to a mistaken diag-
nosis of Hodgkin’s lymphoma (HL). TCR gene rearrangements
are found in 70% of cases. On the other hand, immunoglobulin
gene rearrangements are found in only 10% of patients with
AITL.5ctavio Frias de Oliveira (ICESP), Universidade de São Paulo (USP),
bo).
There is no standard treatment for AITL. Consequently,
patients may be treated with different drugs, including
steroids, immunomodulators or by cytotoxic chemotherapy.
 e Terapia Celular. Published by Elsevier Editora Ltda. All rights
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owever, the most commonly used treatment modality is the
yclophosphamide, vincristine, doxorubicin and prednisone
CHOP) regimen, associated or not with etoposide. This treat-
ent is typically followed by autologous hematopoietic stem
ell transplantation. Furthermore, the natural history of AITL
s characterized by several relapses, with a ﬁve-year overall
urvival of 30%.6,7
In this case report, we  analyzed the main clinical charac-
eristics that make AITL diagnosis difﬁcult. As AITL is a rare
isease with a poor prognosis, an early and correct diagnosis
s essential to improve survival and quality of life.
ase  report
 56-year-old man  with generalized lymphadenomegaly
neck, abdomen, inguinal, supraclavicular and axillar regions)
ame to the Instituto do Câncer do Estado de São Paulo for
reatment. The disease was ﬁrst noticed three months pre-
iously. The initial lymph node biopsy, performed in another
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igure 1 – Immunophenotype by ﬂow cytometry of the periphera
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hospital, suggested nodular sclerosis HL. It was described as
a lymphoid inﬁltrate in a background of eosinophils, promi-
nent vessels and large cells, suggestive of Reed-Sternberg cells
(CD45+, CD3− CD20−, CD30+, CD15+, and EBV negative).
At admission, the complete blood count showed 10.2 g/L
hemoglobin, 12.4 × 109/L white blood cell count with
5.4 × 109/L lymphocytes and 270 × 109/L platelets. Leuko-
cyte immunophenotyping by ﬂow cytometry showed 11% of
mCD3− CD5+, CD4bright, CD8− and CD26partial lymphoid T-cells
(Figure 1). Furthermore, a bone marrow biopsy demonstrated
absence of lymphoma inﬁltration.
The patient was submitted to a ﬂuorine-18 ﬂuorodeoxyglu-
cose positron emission tomography scan that showed
increased uptake of FDG located in superﬁcial and deep
lymph node chains. The exam also indicated a reversal of the
metabolic pattern between liver and spleen.A review of the histological specimens from the previ-
ous biopsy at our center revealed atypical lymphoid cells
with expansion in the paracortical zone and a moderate
number of eosinophils. However, we did not repeat the
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Figure 2 – Section of lymph node biopsy showing (A) immunoperoxidase (IP) CD2 showing lymphoid cells CD2+; (B)
polymorphic inﬁltrate including eosinophils and small lymphocytes (hematoxylin–eosin 400×); (C) IP stain showing
lymphoid cells CD10+; (D) IP stain for CD21 showing dendritic follicular cells; (E) IP stain for CD31 showing a high quantity of
vessels.
immunohistochemical analysis in this sample because it was
very  small. Therefore, another biopsy was indicated, and a
core biopsy was chosen because it could be done faster. The
histological analysis of the new material was compatible with
reactive lymphadenopathy.
In the next few days, the patient’s condition worsened.
In the meantime, another biopsy was performed, this time a
surgical lymph node biopsy. However, the immunochemistry
analysis was incomplete when the patient’s condition became
aggravated. As the revision of the initial biopsy was compati-
ble with HL, and due to the quick deterioration in the patient’s
performance status, our team opted to start treatment for HL
with the doxorubicin, bleomycin, vinblastine, and dacarbazine
(ABVD) regimen.
After two ABVD cycles the patient developed severe pan-
cytopenia. The treatment was interrupted due to toxicity. As
it was not the expected clinical response, the diagnosis of HL
was once more  questioned. At that time, a new bone marrow
biopsy was made, and the histology showed that the bone mar-
row tissue was totally substituted by ﬁbrosis. Simultaneously,
the results of a polymerase chain reaction (PCR) evaluationof the monoclonal rearrangement of the TCR-gamma gene
became available, and they were positive: these new data sug-
gested a mature T-cell lymphoproliferative disease.
A few days later, the immunohistochemistry of the exci-
sional lymph node biopsy was completed and the diagnosis
of AITL was conﬁrmed (Figure 2). In the meantime, the
patient’s clinical condition deteriorated drastically, so another
appropriate chemotherapeutic scheme was not prescribed.
Unfortunately, the patient died in a short period due to respi-
ratory complications.
Discussion
AITL is an aggressive malignancy. It is the second most
common peripheral T-cell lymphoma in Western countries.
Although many  patients achieve complete remission, dis-
ease relapse is frequent, and the three-year overall survival
is less than 50%. The clinical symptoms of AITL are not spe-
ciﬁc and, consequently, the diagnosis can be complex and
sometimes delayed. The clinical features of AITL are more
related to immune dysfunction than to tumor growth. For
oter. 
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xample, AITL symptoms include skin rash, fever, generalized
ymphadenopathy and polyclonal hypergammaglobulinemia,
hich are common features of infections and autoimmune
isorders.3
The gold standard for AITL diagnosis is excisional lymph
ode biopsy. However, to save time and to avoid exposure to
nvasive procedures, many  centers perform a core biopsy to
btain samples for pathological analyses. Unfortunately, the
amples obtained by core biopsy can be insufﬁcient to per-
orm a complete immunohistochemical panel and ensure the
orrect diagnosis.
Previous studies have shown that the accuracy of a lym-
homa diagnosis based on core biopsies varies from 68% to
4%.8 Inadequate core biopsies are associated with misdiag-
oses or delayed diagnoses. Gupta et al. compared lymph node
iopsies acquired with either ﬁne-needle aspiration or sur-
ical excision in 100 patients. They found that the rates of
ccurate diagnoses based on ﬁne-needle aspirations were 77%
n reactive hyperplasia, 75% in NHL, and 85% in metastatic
arcinoma. A recent meta-analysis showed that core biopsies
rovided adequate material for histology in 95% of cases, par-
icularly in salivary gland lesions, but inadequate material in
9 (2.6%) cases of lymphadenopathies of the head and neck.
n differentiating between malignant lymphoma and reactive
ymph nodes, core biopsies showed a high false-negative rate
nd a low negative predictive value (85%).9
A full histological and immunohistochemical analysis of
he lymph node is essential for the differentiation between
ITL and other diseases. For example, it can differentiate
etween large cells with two or more  nuclei, which are fre-
uently observed in AITL tumor microenvironments, and
eed-Sternberg cells.3,4 In the present case study, the small
mount of tissue was insufﬁcient to perform an expanded
mmunohistochemical panel, and consequently, the diagnosis
as incorrect.
Singh et al. demonstrated that 17/17 patients with AITL
n the leukemic phase harbored a distinct population of
CD3−/CD4+ T-cells in the peripheral blood. Furthermore, this
henotype was highly speciﬁc to AITL because it was found
n only 1/40 patients with other T-cell lymphomas in the
eukemic phase. They showed that this phenotype provided a
ositive predictive value of 94% for a diagnosis of AITL. Those
uthors concluded that immunophenotyping peripheral blood
ith ﬂow cytometry might be a useful method for achieving
 differential diagnosis of AITL, even though the aberrant T-
ell population occurs at a very low frequency in peripheral
lood.10 Therefore, this assay should be part of lymphoma
nvestigations, especially in inconclusive cases, because it can
ave time and improve the accuracy of diagnosis.
In this case report, we  describe a case of AITL that was
rroneously treated as HL. We state that this mistaken diag-
osis was mainly a consequence of an insufﬁcient biopsy
ample, which led to an incomplete histological analysis. We
ecommend that in refractory cases a complete revision of2 0 1 6;3 8(1):82–85 85
the initial biopsy should be performed as soon as possible.
We also strongly recommend that to obtain an accurate and
precise diagnosis for lymphoma, excisional biopsies should
be performed instead of core biopsies. Ancillary studies, such
as peripheral blood immunophenotyping and PCR detection
of TCR rearrangements, are very important tools to establish
differential diagnoses, and should be part of the investigation
to improve the accuracy or to conﬁrm the diagnosis of AITL.
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